BYHEALTH CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.12 CNY | -.--% |
|
-0.53% | -11.22% |
| Apr. 25 | Byhealth Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 12 | Byhealth Co., Ltd Approves Cash Dividend for the Year 2023 | CI |
| Sales 2024 * | 10.2B 1.41B | Sales 2025 * | 11.21B 1.55B | Capitalization | 25.72B 3.55B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.87B 258M | Net income 2025 * | 2.1B 290M | EV / Sales 2024 * | 2.32 x |
| Net cash position 2024 * | 2.07B 286M | Net cash position 2025 * | 2.14B 295M | EV / Sales 2025 * | 2.1 x |
| P/E ratio 2024 * |
13.8
x | P/E ratio 2025 * |
12.3
x | Employees | 3,745 |
| Yield 2024 * |
4.54% | Yield 2025 * |
5.32% | Free-Float | 25.61% |
More Fundamentals
* Assessed data
More news
| 1 week | -0.53% | ||
| 1 month | -4.55% | ||
| 3 months | -10.53% | ||
| 6 months | -17.38% | ||
| Current year | -11.22% |
1 week
15.04
15.43
1 month
15.0416.15
Current year
14.1817.84
1 year
14.1824.58
3 years
14.1837.57
5 years
14.1737.90
10 years
10.3337.90
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Cheng Lin
CEO | Chief Executive Officer | 56 | 11-06-30 |
Bai Lin He
DFI | Director of Finance/CFO | - | 23-08-23 |
Zhuo Yi Wu
CHM | Chairman | 46 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yun Chao Liang
CHM | Chairman | 55 | 08-09-15 |
Hui Tang
BRD | Director/Board Member | 56 | 08-09-15 |
Shui Sheng Liang
BRD | Director/Board Member | 59 | 11-09-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 15.12 | -.--% | 6,158,927 |
| 24-05-30 | 15.12 | -.--% | 5,432,450 |
| 24-05-29 | 15.12 | -0.53% | 6,094,500 |
| 24-05-28 | 15.2 | -1.23% | 5,597,900 |
| 24-05-27 | 15.39 | +1.25% | 7,602,972 |
End-of-day quote Shenzhen S.E., May 30, 2024
More quotes
Byhealth Co Ltd is a China-based company mainly engaged in the research, development, production and sales of dietary nutritional supplements. The Company's main products include glucosamine chondroitin vitamin D calcium tablets, natto red yeast and ginkgo leaf capsules, pueraria curcuma collagen tablets, donkey-hide gelatin angelica astragalus tablets, fish oil soft capsules, glucosamine chondroitin sulfate collagen peptide tablets and glucosamine chondroitin sulfate calcium tablets. The Company's main product categories include immune-boosting products, women's health products, bone health products and vitamins. The Company's products are mainly sold online and offline through brands such as By-Health, Jianliduo and Lifespace. The Company mainly conducts its businesses in domestic and overseas markets.
Sector
Food Processing
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.12
CNY
Average target price
22.19
CNY
Spread / Average Target
+46.77%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.22% | 3.55B | |
| +11.85% | 8.05B | |
| +5.29% | 7.59B | |
| +2.63% | 6.07B | |
| -2.80% | 3.85B | |
| -7.04% | 1.28B | |
| -32.50% | 1.03B | |
| +12.52% | 971M | |
| -15.69% | 813M | |
| +2.88% | 731M |
- Stock Market
- Equities
- 300146 Stock
